Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial

Phase 4

Conditions: Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage

Interventions: Drug: Clopidogrel+aspirin
Drug: Clopidogrel

First Posted Date: 2018-02-13

Last Posted Date: 2020-10-19

Lead Sponsor: Shenyang Northern Hospital

Target Recruit Count: 7700

Registration Number: NCT03431142

Locations: 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Phase 1

Completed

Conditions: Elevated Lipoprotein(a)
Cardiovascular Diseases

Interventions: Drug: ISIS 681257
Drug: Clopidogrel

First Posted Date: 2018-01-05

Last Posted Date: 2018-04-05

Lead Sponsor: Akcea Therapeutics

Target Recruit Count: 18

Registration Number: NCT03392051

Locations: 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada

Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

Phase 4

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Clopidogrel

First Posted Date: 2017-12-28

Last Posted Date: 2017-12-28

Lead Sponsor: Zealand University Hospital

Target Recruit Count: 103

Registration Number: NCT03385538

Locations: 🇩🇰
Zealand University Hospital, dept of neurology, Roskilde, Denmark

Efficacy and Safety of Low-dose Ticagrelor

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: ticagrelor
Drug: clopidogrel

First Posted Date: 2017-12-22

Last Posted Date: 2019-09-30

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 3043

Registration Number: NCT03381742

Locations: 🇨🇳
Thromboela-Stogram, Beijing, China

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

Phase 4

Recruiting

Conditions: Coronary Artery Disease
Percutaneous Coronary Intervention

Interventions: Drug: Berberine
Drug: Standard treatment
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2017-12-20

Last Posted Date: 2024-11-15

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 64

Registration Number: NCT03378934

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Phase 3

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2017-11-30

Last Posted Date: 2021-01-22

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 514

Registration Number: NCT03357874

Locations: 🇫🇷
APHM, Marseille, France

Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
NSTEMI - Non-ST Segment Elevation MI
Coronary Angioplasty

Interventions: Drug: Clopidogrel

First Posted Date: 2017-11-01

Last Posted Date: 2019-12-23

Lead Sponsor: Laboratoires Teriak

Target Recruit Count: 167

Registration Number: NCT03329261

Locations: 🇹🇳
HMPIT, Ben Arous, Tunisia

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Phase 3

Completed

Conditions: Kidney Failure
Hemodialysis Fistula Thrombosis

Interventions: Drug: Clopidogrel
Drug: Placebo

First Posted Date: 2017-09-21

Last Posted Date: 2017-09-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 877

Registration Number: NCT03289520

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

and more 6 locations